Jennerex Biotherapeutics is a private, clinical-stage biotherapeutics company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors. Our lead product Pexa-Vec (JX-594) is currently in a randomized Phase 2b clinical trial for hepatocellular carcinoma (HCC) and Phase 2 clinical development for colorectal cancer (CRC) and kidney cancer (RCC). In a recent Phase 2 dose comparison clinical trial published in Nature Medicine, high dose Pexa-Vec was shown to significantly improve survival compared to low dose Pexa-Vec (14.1 months vs. 6.7 months, N=30), with a highly tolerable safety profile in patients with advanced primary HCC. To date, Pexa-Vec has been safely administered to over 230 patients in 11 different clinical studies.
Pexa-Vec is the lead product candidate from Jennerex's proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform, which builds on the natural attributes of vaccinia viruses to engineer highly targeted, oncolytic immunotherapies with minimal side effects. Click here to learn more about SOLVE™.
Pexa-Vec and other product candidates under development are designed to attack cancer through three synergistic and complementary mechanisms of action: 1) Rapid de-bulking of tumors via direct killing of tumor cells 2) Activation of an antivascular effect with rapid tumor vascular knockout and 3) Induction of a durable immune response. Clinical trials of Pexa-Vec using both intratumoral and intravenous administration are being conducted in multiple tumor types.
We are headquartered in San Francisco and have research and development operations in Ottawa, Canada (OHRI labs) and Pusan, South Korea (SillaJen labs)